#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hereditary haemorrhagic telangiectasia Waldenstrom's macroglobulinaemia refractory Autoimmune myositis Neovascular age-related macular degeneration Aplastic anaemia Glomerulonephritis rapidly progressive Palmoplantar pustulosis Non-Hodgkin's lymphoma unspecified histology indolent Hyperinsulinism Leiomyosarcoma recurrent Follicle centre lymphoma follicular grade I, II – III Non-small cell lung cancer metastatic Anti-myelin-associated glycoprotein antibodies positive Gastrooesophageal cancer Cytomegalovirus infection More trials…

    Learn about Rare Diseases

    Angiosarcoma metastatic – Diagnostics Combined immunodeficiency – Life with Disease Short-bowel syndrome – Treatment Prader-Willi syndrome – Treatment Isodicentric chromosome 15 syndrome – Treatment Cytokine release syndrome Skin angiosarcoma – Treatment Netherton’s syndrome – Diagnostics Shprintzen-Goldberg syndrome – Treatment Pulmonary sarcoidosis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Olodaterol Bemcentinib ULVIPRUBART VTX2735 SODIUM BI 456906 Casirivimab CANNABINOL Gen3017 Ttf-Ngr FG001 Elacestrant Dihydrochloride Ascorbic Acid Bp Mrna-3210 Tenofovir Disoproxil Chloride Ion Tipapkinogene Sovacivec YOHIMBINE HYDROCHLORIDE Vobramitamab Duocarmazine Fedratinib Tipiracil More therapies…

    Learn about Your Condition

    Neonatal respiratory failure Patent ductus arteriosus Vaginal cancer Acute lymphocytic leukaemia Glucose tolerance impaired Demyelination Myocarditis post infection Dyspepsia Pyoderma Intermittent claudication Frostbite Amyotrophic lateral sclerosis Acarodermatitis Methylmalonic acidaemia Escherichia infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Vas-Oxy Kft.

Vas-Oxy Kft.

Vizonto Utca 7, Szombathely, 9700, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

    Recruiting

    2 1
    Bulgaria Denmark Germany Greece Hungary Italy +2

  • Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Belgium Bulgaria Czechia Denmark Finland +12

  • Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Ro7790121
    Austria Belgium Bulgaria Croatia Czechia France +8

  • Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Heart failure with preserved ejection fraction
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Austria Bulgaria Czechia France Germany Greece +8

  • Study of RO7790121 Compared to Placebo for Treatment of Adults with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Ro7790121
    Austria Belgium Bulgaria Croatia Czechia Denmark +10

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!